Treatment of Renal Anemia in Patients With Hemodialysis Using Hypoxia-inducible Factor (HIF) Stabilizer, Roxadustat: A Short-term Clinical Study
Treatment of Renal Anemia in Patients With Hemodialysis Using Hypoxia-inducible Factor (HIF) Stabilizer, Roxadustat: A Short-term Clinical Study
复制标题
DOI：
10.21873/invivo.12892
复制
发表时间：
2022-07-01
期刊：
影响因子：
2.3
通讯作者：
Horii, Yasuhiro
中科院分区：
文献类型：
--
作者：
Mima, Akira;Horii, Yasuhiro
背景/目的：肾性贫血是慢性肾脏病(CKD)和血液透析患者的主要并发症，增加了发病率和死亡率。Roxadustat是一种新型口服缺氧诱导因子(HIF)脯氨酸羟基酶抑制剂(PHI)，用于治疗肾性贫血。与促红细胞生成剂(ESA)不同，洛沙度坦能生理性地提高促红细胞生成素水平，改善疗效。Roxadustat获得美国食品和药物管理局(FDA)的批准并不算太久。因此，只有少数研究报道了使用罗沙度斯特治疗肾性贫血。患者和方法：在这项研究中，我们评估了罗沙度坦在血液透析(HD)患者中的疗效。本研究共纳入9例HD患者(年龄72+/-10岁)。患者首次接受罗沙度斯特治疗或改用ESA(5~10 mg，透析后每周3次)。观察期为5.3+/-2.9个月。结果：洛沙度坦治疗有效地提高并维持了血红蛋白水平。血清铁蛋白和C反应蛋白水平有下降趋势，但差异无统计学意义。在研究期间，所有患者都没有观察到明显的不良反应。结论：洛沙度坦治疗血液透析患者肾性贫血疗效确切，耐受性较好。
Background/Aim: Renal anemia is a major complication in patients with chronic kidney disease (CKD) and hemodialysis, increasing morbidity and mortality. Roxadustat is a novel oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI), which is administrated for renal anemia. Different from erythropoiesis-stimulating agents (ESAs), Roxadustat could increase erythropoietin physiologically, improving the therapeutic effects. It has not been so long since Roxadustat was approved by the U.S. Food and Drug Administration (FDA). Thus, only a few studies have reported on the treatment of renal anemia using Roxadustat. Patients and Methods: In this study, we evaluated the efficacy of Roxadustat in patients undergoing hemodialysis (HD). Nine patients under HD (72 +/- 10 years old) were enrolled in this study. Patients received Roxadustat first time or changed from ESAs (5-10 mg, 3 times a week after HD). Observation period was 5.3 +/- 2.9 months. Results: Roxadustat treatment effectively increased and maintained hemoglobin levels. Levels of ferritin and C-reactive protein tended to decrease, but the difference was not statistically significant. No significant adverse effects were observed in all patients during the study. Conclusion: Roxadustat is effective and relatively tolerant for treating renal anemia in patients subjected to hemodialysis.